Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Few Early Alzheimer’s Patients Qualify for Lecanemab

Few people with early Alzheimer’s disease met eligibility criteria for the new anti-amyloid monoclonal antibody treatments lecanemab (Leqembi) and aducanumab (Aduhelm), cross-sectional data from the Mayo Clinic Study of Aging showed. Of 237 people with mild cognitive impairment or mild dementia and increased brain amyloid on PET, clinical trial inclusion and exclusion criteria narrowed the […]

DBN Health News